Repligen: Q3 Earnings Snapshot

Repligen Corp. (RGEN) reported a Q3 loss of $38.4M, or 68 cents per share, but adjusted earnings of 53 cents per share, beating estimates. Revenue was $209.3M, also exceeding forecasts. The company expects full-year earnings of $2.05-$2.09 per share.

Original reporting
Published Oct 27, 2026, 11:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The earnings beat and raised guidance provide a fresh catalyst that could drive short‑term price movement.

02

Market read

First‑report earnings release with beat on both revenue and EPS, offering a clear trading opportunity.

03

What to watch

Guidance range is modest; any miss on FY earnings could reverse any short‑term upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Repligen is a specialty biopharma company focused on protein purification technologies.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen reported Q3 loss of $38.4M and revenue of $209.3M, both beating Zacks estimates, and gave FY earnings guidance of $2.05‑$2.09 per share.

Expected impact

potential upside as the beat may lift the stock

Evidence & confidence

The surprise earnings beat and higher guidance are fresh, material information that can move the price today.

Market effects

Biotech and specialty pharma may see modest sector‑wide optimism from a mid‑cap earnings beat.

U.S. biotech investors could adjust short‑term positioning in related stocks.

Limited to U.S. and global biotech investors; no broad market effect.

Counterpoint

The loss per share may still weigh on the stock if investors focus on profitability rather than revenue beat.

Key entities

  • Repligen Corp.

    Biotech firm reporting Q3 results.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.